Email
Linkedin
Facebook
Twitter
Copy Link
Loading...
Timely insights from the Economy, Strategy & Finance Center
The US administration has issued several executive orders (EOs) related to the nation’s pharmaceutical supply creating a trifecta of challenges for drug companies regarding pricing, onshoring, and tariffs. The most recent EO on May 12 seeks to lower the price of prescription drugs in the US by implementing a “most favored nation” (MFN) pricing requirement.
The order directs the Secretary of Health and Human Services to communicate price targets to pharmaceutical manufacturers within 30 days to bring US drug prices in line with comparably developed nations.
Separately, there is another EO directing the industry to increase US manufacturing and an in-process US Department of Commerce investigation, which is expected to result in tariffs on pharmaceuticals. The confluence of these factors has been called a “worst-case scenario” for the global pharmaceutical industry.
Why it matters: Price increases and supply chain disruptions are increasingly likely
Members of The Conference Board get exclusive access to Trusted Insights for What’s Ahead® through publications, Conferences and events, webcasts, podcasts, data & analysis, and Member Communities.
No Major Signs of Tariffs in April CPI, Yet
May 13, 2025
US-China De-Escalation Brings Down Sky-High Tariffs
May 12, 2025
Stockpiling Crushes Q1 GDP, Details Show Solid Growth
April 30, 2025
Charts
The proliferation of easy-to-use generative AI requires that policymakers and business leaders each play an important role.
LEARN MORE
Charts
A hyperpolarized environment, diminished trust in our nation’s leaders.
LEARN MORE
IN THE NEWS
Erin McLaughlin on Tariff Policy
April 07, 2025
IN THE NEWS
Erin McLaughlin on Reshoring Factors
April 05, 2025
IN THE NEWS
Erin McLaughlin on US Reshoring
April 02, 2025
IN THE NEWS
Erin McLaughlin: How policy uncertainty may exacerbate infrastructure chall…
March 19, 2025
IN THE NEWS
Erin McLaughlin discusses the latest on tariff policy
March 14, 2025
IN THE NEWS
Alex Heil: Tariff uncertainty weighs on consumers, markets
March 10, 2025
